Pyoderma gangrenosum: A review and update on new therapies

被引：153

作者：

Miller, Jeremiah ^{[1
]}

Yentzer, Brad A. ^{[1
]}

Clark, Adele ^{[1
]}

Jorizzo, Joseph L. ^{[1
]}

Feldman, Steven R. ^{[1
,2
,3
]}

机构：

[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC 27157 USA

[2] Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Ctr Dermatol Res, Winston Salem, NC 27103 USA

[3] Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Ctr Dermatol Res, Winston Salem, NC 27103 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2010年 / 62卷 / 04期

关键词：

adalimumab; alefacept; clinical trials; efalizumab; etanercept; infliximab; INFLAMMATORY-BOWEL-DISEASE; CROHN-DISEASE; TOPICAL TACROLIMUS; ULCERATIVE-COLITIS; EXTRAINTESTINAL MANIFESTATIONS; SYSTEMIC ABSORPTION; CONTROLLED TRIAL; INFLIXIMAB; ETANERCEPT; ADALIMUMAB;

D O I：

10.1016/j.jaad.2009.05.030

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Pyoderma gangrenosum is a rare and often painful skin disease that can be unpredictable in its response to treatment. There is currently no gold standard of treatment or published algorithm for choice of therapy. The majority of data comes from case studies that lack a standard protocol not only for treatment administration but also for the objective assessment of lesion response to a specific therapy. This review provides an update to the treatment of pyoderma gangrenosum with a particular focus on new systemic therapies. (J Am Acad Dermatol 2010:62:646-54.)

引用

页码：646 / 654

页数：9

共 63 条

[31] Dermatologic manifestations of Crohn disease in children: Response to infliximab
Kugathasan, S
Miranda, A
Nocton, J
Drolet, BA
Raasch, C
Binion, DG
[J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2003, 37 (02) : 150 - 154
[32] Pyoderma gangrenosum associated with Crohn disease:: effect of TNF-α blockade with infliximab
Ljung, T
Staun, M
Grove, O
Fausa, O
Vatn, MH
Hellström, PM
[J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (09) : 1108 - 1110
[33] Massone L, 1988, Cutis, V42, P459
[34] McGowan Joseph Wilson 4th, 2004, J Drugs Dermatol, V3, P441
[35] Infliximab for peristomal pyoderma gangrenosum
Mimouni, D
Anhalt, GJ
Kouba, DJ
Nousari, HC
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (04) : 813 - 816
[36] Non-melanoma skin cancer: Importance of gender, immunosuppressive status and vitamin D
Oberyszyn, Tatiana M.
[J]. CANCER LETTERS, 2008, 261 (02) : 127 - 136
[37] ODOM RB, 2000, ANDREWS DIS SKIN CLI, P158
[38] Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept)
Pastor, N
Betlloch, I
Pascual, JC
Blanes, M
Bañuls, J
Silvestre, JF
[J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2006, 31 (01) : 152 - 153
[39] Topical tacrolimus for pyoderma gangrenosum: Another report
Piccirillo, Angelo
Ricciuti, Francesco
[J]. JOURNAL OF DERMATOLOGY, 2006, 33 (03) : 232 - 232
[40] Systemic absorption of topical tacrolimus in pyoderma gangrenosum
Pitarch, G
Torrijos, A
Mahiques, L
Sánchez-Carazo, JL
Fortea, JM
[J]. ACTA DERMATO-VENEREOLOGICA, 2006, 86 (01) : 64 - 65

← 1 2 3 4 5 6 7 →